Stock BHVN BIOHAVEN LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Biohaven Ltd.

Equities

BHVN

VGG1110E1079

Biotechnology & Medical Research

End-of-day quote Nyse
Other stock markets
 06:00:00 2024-05-30 pm EDT 		5-day change 1st Jan Change
35.1 USD -0.37% Intraday chart for Biohaven Ltd. -4.41% -17.99%
May. 29 Biohaven Ltd. Showcases Broad Innovative Portfolio and Pipeline Updates Across Multiple Therapeutic Areas Including Immunology, Neuroscience, Metabolic Disorders and Oncology At Annual Investor R&D Day CI
May. 29 Biohaven Doses First Patient with its Novel Trop-2 Directed Antibody Drug Conjugate BHV-1510 in Advanced or Metastatic Epithelial Tumors CI

Valuation

Fiscal Period: December 2022 2023 2024 2025 2026
Capitalization 1 946.1 3,434 3,099 - -
Enterprise Value (EV) 1 480.7 3,052 2,564 2,423 2,289
P/E ratio -1.09 x -7.47 x -4.82 x -5.46 x -6.44 x
Yield - - - - -
Capitalization / Revenue - - 310 x 215 x 27.8 x
EV / Revenue - - 256 x 168 x 20.5 x
EV / EBITDA -0.85 x -7.11 x -4.66 x -4.03 x -3.65 x
EV / FCF -1.58 x -9.12 x -7.7 x -3.87 x -8.83 x
FCF Yield -63.2% -11% -13% -25.8% -11.3%
Price to Book 1.15 x 8.11 x 6.16 x 5.8 x 5.42 x
Nbr of stocks (in thousands) 68,161 80,234 88,292 - -
Reference price 2 13.88 42.80 35.10 35.10 35.10
Announcement Date 3/23/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net sales 1 - - - 10.01 14.39 111.4
EBITDA 1 - -566.5 -429.1 -550.2 -601.8 -626.6
EBIT 1 - -567.9 -436.1 -640.5 -628.3 -577.2
Operating Margin - - - -6,399.71% -4,367.32% -518.16%
Earnings before Tax (EBT) 1 - -569.8 -409.6 -637 -619.9 -550
Net income 1 -236.4 -570.3 -408.2 -632.6 -627.1 -584.7
Net margin - - - -6,320.64% -4,359.29% -524.9%
EPS 2 -6.940 -12.75 -5.730 -7.286 -6.426 -5.454
Free Cash Flow 1 - -303.8 -334.8 -333 -625.6 -259.3
FCF margin - - - -3,327.54% -4,348.44% -232.75%
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 - - - - - -
Announcement Date 8/10/22 3/23/23 2/29/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 - - - - - - - - 0.00167 11.12 3.162 3.191
EBITDA 1 - - - - - -151.8 -181.8 -132.7 -128.9 -141.6 -128.1 -131.2
EBIT 1 -67.64 -213.4 -77.78 -94.01 -110.5 -153.7 -183.2 -158.4 -153.1 -149.5 -148.8 -150.2
Operating Margin - - - - - - - - -9,167,232.34% -1,344.62% -4,707.48% -4,706.92%
Earnings before Tax (EBT) 1 -67.64 -215.2 -69.55 -88.17 -105.9 -146 -178.9 -158 -152.4 -147.7 -151.2 -152.6
Net income 1 -67.64 -201.1 -70.49 -90.35 -102.6 -144.8 -179.5 -156.5 -152 -149.6 -154.3 -156.2
Net margin - - - - - - - - -9,099,437.13% -1,345.46% -4,878.72% -4,894.2%
EPS 2 -1.750 -3.320 -1.030 -1.320 -1.500 -1.810 -2.200 -1.828 -1.709 -1.639 -1.730 -1.831
Dividend per Share 2 - - - - - - - - - - - -
Announcement Date 11/9/22 3/23/23 5/12/23 7/31/23 11/14/23 2/29/24 5/9/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Net Debt 1 - - - - - -
Net Cash position 1 - 465 382 535 676 810
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow 1 - -304 -335 -333 -626 -259
ROE (net income / shareholders' equity) - -199% -78.5% -112% -97.2% -87.9%
ROA (Net income/ Total Assets) - -142% -64.6% -83.6% -80.3% -85.2%
Assets 1 - 401.9 632.1 757 781.5 686.2
Book Value Per Share 2 - 12.00 5.280 5.700 6.060 6.480
Cash Flow per Share - - - - - -
Capex 1 - 6.07 3.05 3.5 6.84 6.06
Capex / Sales - - - 34.97% 47.56% 5.44%
Announcement Date 8/10/22 3/23/23 2/29/24 - - -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
35.1 USD
Average target price
56.89 USD
Spread / Average Target
+62.08%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
BIOHAVEN LTD. Stock Biohaven Ltd.
-17.99% 3.1B
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. BHVN Stock
  4. Financials Biohaven Ltd.